



Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Varenicline Newbury in Sweden. Approval in Iceland is expected to follow upon finalized national review.

Varenicline Newbury, is a generic version of Champix. A prescription medicine indicated for the treatment of smoking cessation in adults.

“The successful approval of Varenicline highlights Newbury's capability to offer a diverse and comprehensive portfolio. Further to this Varenicline Newbury is filling a gap in the market as few alternatives have been available for patients in the last years.” says Mr Lars Minor CEO of Newbury.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden](#)